Technology
Health
Pharmaceutical

Assertio Therapeutics

$4.87
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ASRT and other stocks, options, ETFs, and crypto commission-free!

About

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. Read More The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Employees
116
Headquarters
Lake Forest, Illinois
Founded
1995
Market Cap
312.58M
Price-Earnings Ratio
11.55
Dividend Yield
0.00
Average Volume
1.00M
High Today
$5.09
Low Today
$4.80
Open Price
$4.90
Volume
392.83K
52 Week High
$9.48
52 Week Low
$3.37

Collections

Technology
Health
Pharmaceutical
Therapy
US
North America

News

Guru Focus11h

Weekly CFO Buys Highlight

According to GuruFocus Insider Data, the recent chief financial officer buys were Forterra Inc. (NASDAQ:FRTA), HC2 Holdings Inc. (NYSE:HCHC) and Assertio Therapeutics Inc. (NASDAQ:ASRT). Forterra CFO bought 36,745 shares Executive Vice President and CFO Charles Rodney Brown bought 36,745 shares for $4.16 per share on March 15. Since then, the share price has declined 1.92%. Forterra has a market cap of $261.940 million; its shares were traded around $4.08. The company has a price-sales ratio of 0.18. Fo...

23
ReutersMar 19

Assertio Therapeutics beats investor lawsuit over opioid marketing

Assertio Therapeutics Inc has won the dismissal of a shareholder lawsuit accusing it of misleading investors about the extent to which its growth was fueled by marketing its Nucynta opioid painkillers for off-label purposes.

55
Guru FocusMar 11

Assertio Therapeutics Inc (ASRT) Files 10-K for the Fiscal Year Ended on December 31, 2018

Assertio Therapeutics Inc (NASDAQ:ASRT) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Depomed Inc is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system.

77

Earnings

$0.08
$0.19
$0.31
$0.42
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.